Why is Hester Bios falling/rising?

As of 13-Oct, Hester Biosciences Ltd's stock price is currently at 1,699.90, reflecting a decrease of 40.7 points or 2.34%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total decline of 3.58% during this period. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has declined by 5.53%, and over the last month, it has seen a significant drop of 17.96%. While the company reported a growth in net profit of 145.1% and has declared positive results for five consecutive quarters, concerns about its high Debt to EBITDA ratio of 3.49 times and poor long-term growth rates have negatively impacted investor sentiment.
In the broader market context, Hester Biosciences' recent performance contrasts sharply with the Sensex, which has gained 0.66% over the past week. The stock's year-to-date return is down 28.95%, while the Sensex has increased by 5.36% during the same period. This underperformance may indicate a lack of confidence among investors, as evidenced by the negligible domestic mutual fund holdings in the company, suggesting that institutional investors are wary of its valuation and growth prospects. Overall, the combination of poor short-term performance, high debt levels, and low profitability metrics has contributed to the stock's decline.